Results 21 to 30 of about 3,090 (189)

Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.

International Journal of Molecular Medicine, 2013
The molecular chaperone heat shock protein 90 (Hsp90) is involved in the maturation and stabilization of a wide range of oncogenic client proteins for oncogenesis and malignant cell proliferation, which renders this protein a promising target in the ...
Segawa, Tatsuya, Bando, Shin-Ichi, 468407, Tanaka, Aya, 468406, Fujii, Yoshihiro, 468405, 岡安 隆一, 468404, 468403, 468402, 468401, 468400, Ohnishi, Ken, Okayasu, Ryuichi, Kubota, Nobuo   +15 more
core   +5 more sources

Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution [PDF]

Frontiers in Immunology, 2021
Characterizing and understanding the antibody binding interface have become a pre-requisite for rational antibody design and engineering. The antigen-binding site is formed by six hypervariable loops, known as the complementarity determining regions ...
Monica L. Fernández-Quintero, Katharina B. Kroell, Florian Hofer, Jakob R. Riccabona, Klaus R. Liedl   +4 more
doaj   +3 more sources

The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining

Radiotherapy and Oncology, 2016
PU-H71 is a purine-scaffold Hsp90 inhibitor developed to overcome limitations of conventional Hsp90 inhibitors. This study was designed to investigate the combined effect of PU-H71 and heavy ion irradiation on human tumor and normal cells.journal ...
Huizi Keiko Li, Aya Masaoka, Shigeaki Sunada   +2 more
exaly   +2 more sources

Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2

Biochimica Et Biophysica Acta - Molecular Cell Research, 2013
Heat shock protein 90 (Hsp90) has recently emerged as an attractive therapeutic target in cancer treatment because of its role in stabilizing the active form of a wide range of client oncoproteins.
Alexandre Prola, Christophe Lemaire
exaly   +2 more sources

FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia [PDF]

Current Issues in Molecular Biology
Targeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML).
Katja Seipel, Harpreet Mandhair, Ulrike Bacher, Thomas Pabst   +3 more
doaj   +2 more sources

HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment [PDF]

Oncogene, 2017
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells in the hematopoietic system and lymphoid tissues. Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in the treatment of the disease, the
Zhen, C, Lee, J, Guo, A, Lu, P, Wang, YL, Chiosis, G   +5 more
core   +7 more sources

HSP90 inhibitörü PU-H71’in ve radyoterapi ile kombine uygulamasının metastatik meme kanseri üzerine etkisinin araştırılması [PDF]

, 2016
HSP90 (Isı Şok Proteini 90) birçok hücresel proteinin stabilizasyonunu sağlamaktadır. Stresli durumlarda ekspresyonu artan HSP90 hücresel proteinleri degredasyondan korur. HSP90'nın ekspresyon profili normal ve malign hücrelerde farklılık göstermektedir.
Kale, Şule
core   +3 more sources

Abstract 5766: The Hsp90 inhibitor PU-H71 is a potent suppressor of metastasis in triple-negative breast cancer models

Cancer Research, 2010
Background: Triple-negative breast cancer (TNBC) characterized by estrogen and progesterone receptor and HER-2-negativity is a particularly aggressive tumor with currently no effective targeted therapies.
Paula Bos, Leandro Cerchietti, Ari Melnick, Hector Peinado, Eloisi Caldas Lopes, Simon Lavotshkin, Gabriela Chiosis, David Lyden   +7 more
core   +2 more sources

Hsp90 Inhibitor PU-H71 [PDF]

, 2020

core   +2 more sources

Epichaperome-targeted myocardial imaging by ¹²⁴I-PU-H71 PET. [PDF]

Clin Transl Imaging, 2023
Abstract Background 124I-PU-H71 is an imaging biomarker of epichaperome formation, localizing in tissues under chronic stress. A first-in-human positron emission tomography (PET) trial in cancer patients revealed unexpected tracer accumulation in the myocardium.
Mahajan S, Grkovski M, Staton KD, Ravassa S, Domfe K, Strauss HW, Humm JL, Zanzonico PB, Beattie BJ, Cho I, Burnazi EM, Fox JJ, Schöder H, Osborne JR, Youn T, Jhaveri K, Chiosis G, Dunphy MP.   +17 more
europepmc   +3 more sources